Caption Management’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-100
Closed -$1.5K 1735
2024
Q3
$1.5K Sell
100
-499,900
-100% -$8.55M ﹤0.01% 1221
2024
Q2
$14.3M Buy
500,000
+378,000
+310% +$10.8M 0.22% 99
2024
Q1
$3.56M Buy
+122,000
New +$3.75M 0.05% 379
2022
Q2
Sell
-150,000
Closed -$11.4M 1727
2022
Q1
$11.4M Buy
+150,000
New +$10M 0.14% 184
2021
Q1
Sell
-25,000
Closed -$1.5M 1307
2020
Q4
$1.5M Hold
25,000
0.03% 517
2020
Q3
$1.5M Buy
+25,000
New +$1.45M 0.04% 516
2020
Q2
Sell
-60,000
Closed -$2.01M 1136
2020
Q1
$2.01M Buy
+60,000
New +$2.49M 0.11% 256

Other funds holding PCRX

Caption Management's PCRX Position: Q1 2025 in Review

Caption Management sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 53,844 shares — an estimated $1.01M sold.

Caption Management first reported a position in PCRX in Q3 2020 and held it in 7 quarters. The position peaked at $1.42M in Q1 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Caption Management reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 53,844 Pacira BioSciences shares in Q1 2025, an estimated $1.01M.
  • Caption Management first reported a position in Pacira BioSciences in Q3 2020 and held it in 7 quarters.
  • Caption Management's Pacira BioSciences position peaked at $1.42M in Q1 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.